Trial Profile
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Cotadutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MedImmune
- 14 Oct 2019 Primary endpoint (Percentage change in body weight from baseline (cohort 1 only) has been met published in the Journal of Clinical Endocrinology and Metabolism
- 14 Oct 2019 Primary endpoint (Percentage change in glucose area under the curve (cohort 1 only) has been met published in the Journal of Clinical Endocrinology and Metabolism
- 14 Oct 2019 Results published in the Journal of Clinical Endocrinology and Metabolism